KAIMRC and Flagship Pioneering Form $70M Partnership for Genetic Disease Clinical Trials in Saudi Arabia
核心洞察
King Abdullah International Medical Research Center and Flagship Pioneering (搜索) announced a strategic partnership to conduct early-phase clinical trials of novel genetic disease therapies in Saudi Arabia.
The collaboration will initially focus on three Phase 1 programs and one Phase 2 program from Flagship-founded companies targeting genetic diseases (搜索) with high unmet medical need.
Saudi investors will commit $70 million to participating U.S.-based companies as part of the partnership framework.
King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia's largest medical research institution, has partnered with Cambridge-based Flagship Pioneering (搜索) to establish a clinical trial framework for novel genetic disease therapies. The strategic collaboration, announced at the U.S.-Saudi Investment Forum in Washington, D.C., represents a significant expansion of clinical research capabilities in the Kingdom of Saudi Arabia.
Clinical Trial Framework and Investment
Under the Memorandum of Understanding, the partnership will initially focus on three Phase 1 programs and one Phase 2 program from three Flagship-founded companies targeting genetic diseases (搜索). The collaboration is designed to enable global Phase 1 and 2 clinical trials of medicines addressing genetic diseases with high unmet medical need, particularly those of significant relevance to patients in Saudi Arabia.
Saudi investors will collectively commit an initial investment of $70 million (approximately SAR 262.5 million) to the participating U.S.-based companies. The partnership framework allows for potential expansion to additional programs over time.
Infrastructure and Capabilities
The collaboration will leverage state-of-the-art facilities across multiple Saudi institutions, including KAIMRC, the Ministry of National Guard Health Affairs (搜索) (MNGHA), and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS). Flagship companies will gain access to advanced patient care units and clinical laboratories within this integrated healthcare ecosystem.
KAIMRC brings significant research infrastructure to the partnership, including an ISO-accredited Saudi Biobank with more than 60,000 samples and a Cellular and Molecular Biobank operating under Good Manufacturing Practice standards for CAR-T cell therapy. The center maintains over 100 global partnerships and earned accreditation from the Association for the Accreditation of Human Research Protection Programs in 2023.
Strategic Vision
"This partnership marks a significant milestone in our ambition to establish Saudi Arabia as a leader in innovative clinical trials and Biotech Hub," said H.E. Dr. Bandar AlKnawy, Chief Executive Officer of the Ministry of National Guard Health Affairs (搜索) and President of King Saud bin Abdulaziz University for Health Sciences. "By leveraging the robust ecosystem at the MNGHA, KAIMRC, and KSAU-HS, we aim to attract premier clinical research that will not only elevate our healthcare capabilities but also propel our national biotechnology strategy forward."
Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering (搜索), emphasized the global impact potential: "By combining the pioneering science of Flagship and our companies with KAIMRC's state-of-the-art facilities and resources, we have a clear opportunity to advance American innovation at home and abroad and expand global access to transformative medicines."
Flagship Pioneering Portfolio
Flagship Pioneering (搜索) operates with $14 billion of assets under direction as of July 2024 and has originated more than 100 scientific ventures since 2000. The current ecosystem comprises over 40 companies, including notable biotechnology firms such as Moderna, Sana Biotechnology, Tessera Therapeutics (搜索), and Generate Biomedicines.
The partnership represents a strategic alignment between American biotechnology innovation and Saudi Arabia's expanding clinical research infrastructure, positioning both entities to advance therapeutic development for genetic diseases (搜索) on a global scale.